Edwards Lifesciences (EW) — Q2 2026 Earnings Preview

1. Earnings Preview

Key Takeaway: Setup is constructive but not a layup — consensus has drifted modestly higher since Q1's beat, the bar is reasonable, and the biggest swing factor is whether TMTT momentum can sustain its ~40% growth trajectory into a tougher H2 compare.

Heading into Q2 2026, Edwards carries genuine momentum from a strong Q1 beat (12.7% total sales growth, adjusted EPS of $0.78 vs. consensus ~$0.73) and a subsequent guidance raise to 9–11% full-year sales growth. Consensus for Q2 sits at ~$1.70B in revenue and ~$0.75 adjusted EPS — a bar that reflects the raised full-year framework but also embeds some caution around tougher H2 compares and the phasing of strategic investments. Management's tone at the May 12 BofA Healthcare Conference was notably confident, reiterating TMTT on track for $750M (40% growth at midpoint) and flagging that international TAVR grew faster than the U.S. in Q1, a trend that could persist. Estimate revisions have been modestly positive since the Q1 print — Q2 EPS consensus has moved from ~$0.73 to ~$0.75 — suggesting the street is gradually gaining conviction without getting ahead of itself. The stock has outperformed XLV (+6.1% vs. +9.0% for XLV since Q1 earnings), implying the market has partially priced in continued execution but has not gone euphoric. The single biggest wildcard is the CMS NCD draft decision memo for TAVR (expected by June 15, 2026): if the draft signals a more flexible coverage framework for asymptomatic patients, it could meaningfully re-rate the long-term TAVR growth narrative and serve as a positive catalyst even before the formal NCD is finalized by year-end.

2. KPIs & Consensus Expectations

Key Takeaway: Consensus reflects a reasonable but not aggressive bar — ~$1.70B revenue (+10.8% YoY) and ~$0.75 adjusted EPS (+11.9% YoY). TMTT growth rate is the bigger swing factor; any deceleration below ~35% would disappoint, while upside surprise there could drive the stock meaningfully higher.

Table 1 — Current Quarter Snapshot (Q2 2026)

Source: Visible Alpha Consensus and Actuals Data. All consensus figures represent latest available estimates as of July 22, 2026.

Table 2 — Beat/Miss History (Last 8 Quarters) — Top 2 KPIs: Total Revenue & Adjusted EPS

Pattern: EW has beaten revenue consensus in 7 of the last 7 fully-reported quarters, and beaten adjusted EPS in 6 of 7 — a consistent track record of modest upside that sets a constructive but not complacent expectation for Q2 2026. The one EPS miss (Q4 2025) was driven by investment phasing, not demand weakness.

Source: Visible Alpha Consensus and Actuals Data.

3. Guidance & Commentary Evolution

Key Takeaway: Guidance was raised at Q1 earnings (April 23) and reaffirmed with confidence at the BofA Healthcare Conference (May 12). No formal revisions since then, but management tone remains constructive — particularly on TMTT trajectory and TAVR market growth.

4. Guidance vs. Estimate Revision Tracker

Key Takeaway: Estimates have moved modestly higher since the Q1 print, tracking guidance rather than diverging from it. The gap between consensus and guidance midpoints is narrow and represents cushion rather than risk — particularly for EPS, where consensus sits above the guidance midpoint, suggesting the street expects continued investment phasing benefits.

Estimates have been remarkably stable since the Q1 print — essentially flat across all key metrics — suggesting the street has high conviction in the guidance framework and is not making incremental bets ahead of the print. The slight EPS premium to guidance midpoint reflects the market's expectation that investment phasing will again provide a tailwind, as it did in Q1.

Source: Visible Alpha Consensus and Actuals Data.

5. Stock Performance

Key Takeaway: EW has delivered modest absolute gains since Q1 earnings (+5.8%) but has underperformed XLV (+9.0%) over the same period, suggesting the Q1 beat was well-received but the stock has not re-rated meaningfully higher. Multiple compression (NTM P/E from ~30x to ~27x) indicates earnings growth is driving the stock, not multiple expansion — a healthy setup heading into Q2.

EW vs. XLV (Health Care Select Sector SPDR) vs. S&P 500 (SPY) — Indexed to 100 at Q1 2026 Earnings Date (April 23, 2026). Source: Stock Price Data (Yahoo Finance).

Performance Summary (April 23 – July 22, 2026):

Valuation Context: EW currently trades at NTM P/E of ~27.4x, EV/EBITDA of ~20.2x, and P/FCF of ~32.6x. Over the past 12 months, the stock is up +10.2% but NTM EV/EBITDA has compressed from ~22.2x to ~20.2x, confirming that earnings growth — not multiple expansion — has been the primary driver. The stock peaked at ~$95 in early July before pulling back ~11% to current levels, creating a more attractive entry point ahead of the print.

Source: Stock Price Data (Yahoo Finance); Visible Alpha Consensus and Actuals Data.

6. Material News & Developments

Key Takeaway: The most important post-Q1 development is the CMS NCD draft decision memo for TAVR (expected by June 15, 2026) — a potential structural catalyst for the asymptomatic AS indication that could meaningfully expand the addressable market. The new CFO transition has been resolved cleanly.

• CMS NCD Draft Decision Memo for TAVR (Expected by June 15, 2026): Management flagged at the Q1 earnings call (April 23) that a draft NCD decision memo was expected by June 15, with the final NCD to be in place by year-end. Edwards is seeking a “more flexible NCD where the heart team can decide what operator can be in the room.” Additionally, CMS and FDA announced a new RAPID policy for breakthrough therapies on April 23 — viewed as an incremental positive for early TAVR access.
• New CFO Appointment — Theodora (“Doretta”) Mistras (Effective May 29, 2026): Edwards announced on May 4, 2026 that Mistras would succeed Scott Ullem as CFO, effective May 29. Mistras brings 2+ decades in healthcare investment banking (Goldman Sachs, Citigroup) and CFO experience at Viatris. The transition appears orderly; Mistras was present at the BofA Healthcare Conference on May 12.
• BofA Healthcare Conference (May 12, 2026): CEO Bernard Zovighian reiterated full-year guidance and expressed confidence in the Q2 trajectory. Key quotes: “We feel good about where we are as a company”; TMTT “on track to achieve $750M in revenue, growing 40% at the midpoint”; TAVR NCD “going to be very important” with draft expected mid-June. International TAVR growth outpaced U.S. in Q1, with Europe performing particularly well.
• PROGRESS Trial (Moderate AS) — Results at TCT 2026: Results from the PROGRESS trial studying moderate aortic stenosis patients will be presented at TCT 2026 (later this year). Edwards plans to host a dedicated investor event following the data presentation to discuss commercial implications. This is a potential long-term TAVR market expansion catalyst.
• PASCAL Next-Gen & Tricuspid Indication Expansion (Q4 2026): Next-generation PASCAL technology expected in Q4 2026 for both mitral and tricuspid in the U.S. and Europe. PASCAL U.S. tricuspid launch also expected in Q4. CLASP II TR data for Class 2 tricuspid regurgitation to be presented at TCT 2026, with U.S. approval anticipated thereafter — described by management as “all incremental” upside to current TMTT revenue.
• SAPIEN M3 FDA Approval & Early Commercial Traction: FDA approved SAPIEN M3 in December 2025; launched in the U.S. at year-end. Q1 2026 commercial experience was described as “positive” with physician feedback validating the need for a mitral replacement solution for non-TEER-eligible patients.
• Accelerated Share Repurchase ($500M): During Q1 2026, Edwards entered into an ASR agreement to repurchase $500M in shares. Approximately $1.5B remains under the share repurchase authorization.
• Annual Investor Conference — December 4, 2026 (NYSE): Edwards will host its annual investor conference at the New York Stock Exchange on December 4, 2026. This will likely be a key venue for 2027 guidance and pipeline updates.
• Analyst Rating/PT Activity: No specific rating changes noted in the research context since Q1 earnings. The stock’s recent pullback from ~$95 to ~$84 may prompt PT revisions post-Q2 print depending on results.

7. Peer Commentary & Current-Quarter Read-Through

Key Takeaway: Peer commentary from the last 60 days is broadly constructive for EW’s Q2 2026 setup. Abbott’s Q2 2026 earnings (July 16) are the most direct and positive read-through — confirming strong U.S. TAVR and tricuspid growth, robust Medicare-driven cardio demand, and healthy international structural heart momentum. Boston Scientific’s May 27 conference commentary adds a secondary positive signal on interventional cardiology volumes, though it also flags cath lab capacity competition as a watch item. Medtronic’s Q4 FY26 results (June 3) present a mixed picture: international structural heart strength is a positive read-through, but U.S. structural heart weakness at Medtronic is likely company-specific (share loss to EW) rather than a market signal. Intuitive Surgical’s Q2 2026 results (July 16) flag modest U.S. procedure softness in deferrable procedures from ACA subsidy expiration — a watch item, though TAVR/TMTT are far less deferrable than the benign procedures most affected.

Note on Scope: Only commentary explicitly pertaining to Q2 2026 (April–June 2026) conditions or forward-looking statements made after EW’s Q1 2026 earnings (April 23, 2026) is included below. Retrospective peer-quarter commentary about prior periods has been excluded.

7.1 Abbott (ABT) — Q2 2026 Earnings Call (July 16, 2026) — STRONGEST READ-THROUGH

Relevance: Very High. Abbott’s structural heart portfolio (MitraClip, TriClip, TAVR) directly competes with EW in TMTT and TAVR. Abbott’s Q2 2026 results cover the same calendar quarter as EW’s Q2 2026.

• U.S. Cardio Demand is Inelastic and Accelerating: CEO Robert Ford stated: “Demand for high-acuity life-saving products is very inelastic” and “we’re seeing strong demand for our U.S. cardio business. I’d argue that our U.S. cardio business is performing better than it’s ever been.” Hospital lab volumes were up 13% in Q2. Medicare — the primary payer for TAVR/TMTT — represents “over two-thirds of our U.S. cardio business.”
• TAVR Growing Strongly in the U.S. and Internationally: Ford explicitly noted “good growth in TAVR here in the U.S.” and flagged that Abbott’s international structural heart team “grew double digits in the first half,” with “TAVR up 30% in the first half” internationally. This is a strong positive read-through for EW’s TAVR segment, particularly international, where EW has been gaining share.
• Tricuspid Growing Well: Ford noted “good growth in tricuspid” in the U.S. This validates the broader tricuspid market expansion that underpins EW’s EVOQUE and PASCAL tricuspid growth thesis.
• U.S. Mitral Competitive Intensity — Watch Item: Abbott acknowledged “competitive intensity has increased” in U.S. mitral, with Ford saying “we’ve got to do a better job in mitral.” This is a direct read-through for EW’s TMTT mitral business — EW is likely the beneficiary of Abbott’s mitral share loss, given PASCAL’s differentiated design and SAPIEN M3’s new mitral replacement option.
• Aging Population Tailwind Remains Durable: Ford: “Every day in the United States, you have 10,000 people that turn 65. And age is a driving factor of health care.” This structural tailwind directly supports EW’s TAVR and TMTT addressable market expansion thesis.
• Medicaid vs. Medicare Distinction — Important for EW: Ford clarified that Medicaid cuts are “not a driver of medtech surgical procedures in the United States” — it’s Medicare that matters, and Medicare demand is robust. This directly addresses investor concerns about healthcare policy headwinds for structural heart procedures.

Bottom Line for EW: Abbott’s Q2 2026 results are the most direct and positive peer read-through available. Strong U.S. TAVR growth, robust international structural heart momentum, and inelastic Medicare-driven demand all point to a healthy Q2 environment for EW. The U.S. mitral competitive intensity comment is a potential positive for EW (share gains from Abbott).

Source: Abbott Q2 2026 Earnings Call Transcript, July 16, 2026.

7.2 Medtronic (MDT) — Q4 FY26 Earnings Release (June 3, 2026) — MIXED READ-THROUGH

Relevance: High. Medtronic’s Structural Heart & Aortic segment is EW’s primary TAVR competitor. MDT’s Q4 FY26 ended April 24, 2026, covering approximately the first month of EW’s Q2 2026.

• U.S. Structural Heart & Aortic Declined 4.0% Organically: Medtronic’s U.S. Structural Heart & Aortic revenue fell to $387M from $404M in the prior year period (-4.0% organic). This is a notable negative for Medtronic but is likely a positive read-through for EW — it suggests EW is continuing to gain U.S. TAVR share from Medtronic, consistent with management’s Q1 commentary about “slightly increased” U.S. competitive position.
• International Structural Heart & Aortic Grew 6.4% Organically: Medtronic’s international Structural Heart & Aortic revenue grew to $575M (+6.4% organic). This is a positive read-through for the international TAVR market broadly, supporting EW’s international growth narrative.
• Overall Cardiovascular Portfolio Strong (+10.1% Organic): Medtronic’s broader cardiovascular portfolio grew 10.1% organically in Q4 FY26, driven by other segments (cardiac rhythm, coronary). This confirms a healthy overall cardiovascular procedure environment.
• FY27 Guidance: 6.75%–7.25% Organic Revenue Growth: Medtronic’s CFO stated: “We are entering the year with strong momentum, a resilient operating foundation, and a clear path to deliver durable growth.” No specific structural heart forward guidance provided.

Bottom Line for EW: Medtronic’s U.S. structural heart weakness is most likely EW’s gain — a positive read-through for EW’s U.S. TAVR share trajectory. International structural heart growth at Medtronic confirms a healthy global TAVR market. The partial quarter overlap (April only) limits the read-through precision.

Source: Medtronic Q4 FY26 Earnings Release, June 3, 2026.

7.3 Boston Scientific (BSX) — Bernstein Strategic Decisions Conference (May 27, 2026) — CONSTRUCTIVE READ-THROUGH WITH CAVEATS

Relevance: Moderate. BSX’s commentary covers Q2 2026 forward conditions and interventional cardiology market health, which is adjacent to EW’s TAVR/TMTT markets.

• No Slowdowns in Interventional Cardiology: CEO Michael Mahoney stated BSX sees “healthy volumes in EP at healthy volumes across interventional cardiology” and has “not seen a slowdown in the overall procedure mix and rate globally.” BSX is comfortable within its Q2 guidance of 5–7% growth. This is a positive read-through for the broader interventional cardiology environment in which TAVR and TMTT procedures occur.
• No Impact from Medicaid Cuts or ACA Subsidy Expiration: Mahoney noted BSX does “not see any slowdowns or significant impact” from Medicaid cuts or ACA premium subsidy expiration on its procedure volumes. This is a positive read-through for EW, whose TAVR/TMTT patients are predominantly Medicare-covered.
• Cath Lab Capacity Competition — Watch Item: BSX flagged “competition for space” in cath labs, with EPs “very, very busy with ablation” leading to fewer stand-alone WATCHMAN procedures. While WATCHMAN-specific, this raises a broader question about cath lab resource allocation that could indirectly affect TAVR/TMTT scheduling. However, TAVR and TMTT are higher-acuity, less-deferrable procedures than WATCHMAN, limiting the direct read-through.
• BSX’s MiRus TAVR Investment — Long-Term Competitive Watch: BSX disclosed a recent investment in MiRus to enter the TAVR market with the SIEGEL valve (8-French system, expected late 2028/early 2029). While not a near-term threat to EW, this signals increasing long-term competitive interest in the TAVR market and validates the market’s attractiveness.
• Strength in Interventional Cardiology and Vascular: Mahoney noted BSX “continues to see strength in Interventional Cardiology and Vascular” — a general positive for the broader cardiac procedure environment.

Bottom Line for EW: BSX’s commentary is broadly constructive for EW’s Q2 environment — no macro headwinds, healthy interventional cardiology volumes, and no ACA/Medicaid impact. The cath lab capacity comment is a minor watch item but unlikely to materially affect TAVR/TMTT given their higher-acuity, less-deferrable nature.

Source: Boston Scientific Bernstein Strategic Decisions Conference Transcript, May 27, 2026.

7.4 Intuitive Surgical (ISRG) — Q2 2026 Earnings Call (July 16, 2026) — CAUTIONARY SIGNAL ON U.S. DEFERRABLE PROCEDURES

Relevance: Moderate (indirect). ISRG’s Q2 2026 results cover the same calendar quarter as EW. While ISRG’s procedure mix (robotic surgery) differs significantly from TAVR/TMTT, its commentary on U.S. patient behavior and hospital capital environment is relevant.

• U.S. Procedure Growth Moderated for Deferrable Procedures: ISRG reported U.S. da Vinci procedure growth of 12% in Q2, but noted this “moderated from recent trends and our expectations at the start of the year, predominantly in procedures that can be deferred.” CFO Jamie Samath attributed a “modest adverse impact” to ACA enhanced premium subsidy expiration.
• Critical Distinction — TAVR/TMTT Are Not Deferrable: ISRG’s CEO Dave Rosa explicitly noted that “the underlying disease burden is unchanged and deferred conditions typically progress and will ultimately require treatment as patients return to care.” TAVR and TMTT address severe and life-threatening structural heart disease — far less deferrable than the benign procedures most affected at ISRG. The ACA subsidy impact is therefore unlikely to materially affect EW’s Q2 volumes.
• U.S. Capital Environment Stable: Samath noted “the U.S. capital environment, at least in our experience, has been stable for some time now” with “healthy system placements in Q2 in the U.S. up 24%.” This is a positive read-through for hospital investment in structural heart programs.
• Japan Reimbursement Positive: New Japanese policies supporting robotic surgery went into effect June 1, including reimbursement for additional procedures. While ISRG-specific, a favorable Japanese reimbursement environment could signal broader policy support for advanced medical technologies, including TAVR, in Japan — a market where EW has been growing strongly.
• Europe: Some Budget Pressure in Certain Markets: ISRG noted “capital pressure in parts of Europe related to macroeconomic impact and shifting governmental priorities.” This is a watch item for EW’s European TAVR business, though EW’s European growth has been driven by physician demand and competitor exit rather than capital spending.

Bottom Line for EW: ISRG’s U.S. procedure softness is largely irrelevant to EW given the non-deferrable nature of TAVR/TMTT. The stable U.S. capital environment and Japan reimbursement tailwinds are modestly positive. European budget pressure is a minor watch item.

Source: Intuitive Surgical Q2 2026 Earnings Call Transcript, July 16, 2026.

7.5 Peer Read-Through Summary Table

8. Insider Transaction Activity

Key Takeaway: All insider transactions since Q1 earnings are sales — no open-market buys. The CEO’s large May 12 sale (36,351 shares, ~$2.9M) is under a 10b5-1 plan and therefore pre-planned. The pattern of routine 10b5-1 sales and one larger discretionary sale (BOBO, May 15–27) is not unusual for a company at this valuation level.

Assessment: No open-market buys were filed in the period. The insider selling activity is dominated by pre-planned 10b5-1 transactions (CEO, CVP TAVR) and a cluster of discretionary sales in mid-May (BOBO, Chopra, Markowitz). The discretionary sales occurred when the stock was trading in the $80–$87 range — below the recent July peak of ~$95. The absence of any open-market buys is not alarming given the stock’s elevated valuation, but the lack of insider buying provides no incremental bullish signal heading into the print.

Source: Insider Transaction Data (SEC Form 4 Filings).